Efektivitas N-Acetylsistein pada Pasien COVID-19
DOI:
https://doi.org/10.55175/cdk.v48i7.99Keywords:
N-Acetylsistein, COVID-19, antiokasidan, antiinflamasiAbstract
COVID-19 disebabkan oleh virus SARS-Cov-2 dan menyebabkan morbiditas dan mortalitas yang tinggi. COVID-19 dapat menyebabkan pneumonia, sindrom gangguan pernapasan akut, perubahan kardiovaskular, dan kegagalan multi organ, yang dianggap berasal dari mekanisme badai sitokin, respons peradangan sistemik, dan serangan sistem kekebalan. N-acetylcysteine (NAC) telah digunakan dalam klinis untuk mengobati pasien sepsis dengan kondisi kritis. NAC memiliki karakteristik antioksidan, antiinflamasi, dan modulasi kekebalan yang bermanfaat menurunkan risiko perburukan COVID-19.
COVID-19 is caused by SARS-Cov-2 virus, and is known to cause high morbidity and mortality. COVID-19 causes pneumonia, acute respiratory distress syndrome, cardiovascular changes, and multi-organ failure, correlated to cytokine storm mechanisms, systemic inflammatory responses, and immune system attacks. N-acetylcysteine (NAC) has been used in clinical practice to treat sepsis patients with critical conditions. NAC has antioxidant, anti-inflammatory, and immune modulation characteristics beneficial to reduce the risk of COVID-19 worsening.
Downloads
References
WHO. Coronavirus disease 2019 (COVID-19). Weekly epidemiological update – 13 January 2021. WHO; 2021.
Marpaung R, Chandra E, Suwanto D. Hiperkoagulabilitas pada kehamilan dengan COVID-19. CDK. 2020;290(47 no. 9):713
ShiZ, PuyoCA. N-Acetylcysteine to combat COVID-19: An evidence review. Ther Clin Risk Manag. 2020;16:1047–55.
Andreou A, Trantza S, Filippou D, Sipsas N, Tsiodras S. N-acetylcysteine (NAC) in a combination of candidate antiviral treatments against SARS-CoV-2. VIVO 2020;34:1567-88
Flora SD, Balansky R, La Maestra S. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19. The FASEB Journal. 2020;34:13186
Van Hecke O, Lee J. N-acetylcysteine: A rapid review of the evidence for effectiveness in treating COVID-19. CEBM [Internet]. 2020 April 14 [cited 2021 Jan 19]. Available :https://www.cebm.net/covid-19/n-acetylcysteine-a-rapid-review-of-the-evidence-for-effectiveness-in-treating-covid-19/
Puyo C, Kreig D, Saddi V, Ansari E, Prince O. Case report: Use of hydroxychloroquine and N-acetylcysteine for treatment of a COVID-19 patient. F1000 Res.2020;9:491
Hasan J. N-acetylcysteine in severe COVID-19: The possible mechanism. Int J infect. 2020;7(4):e106361.
Nasi A, McArdle S, Gaudernack G, Westman G, Melief C, Rockberg J, et al. Reactive oxygen species as an initiator of toxic innate immune response in retort to SARSCOV-2 in ageing population, consider N-acetylcystein as early therapeutic intervention. Toxicol Rep. 2020;7:768-71.
Qianwen Z, Yuanrong J, Yan M, Tao W. N-acetylcysteine improves oxidatives stress and inflammatory response in patients with community acquired pneumonia. Medicine J. 2018;97:45.
Liu Y, Wang M, Luo G, Qian X, Wu C, Zhang Y, et al. Experience of N-acetylcystein airway management in the successful treatment of one case os critical condition with COVID-19. Medicine J. 2020;99:42.
Ibrahim H, Perl A, Smith D, Lewis T, Kon Z, Goldenberg R, et al. Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine. Clin Immunol J. 2020;219:108544.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Cermin Dunia Kedokteran
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
